{"id":"NCT01115855","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure","officialTitle":"The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Japanese Subjects With Chronic Heart Failure","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07","primaryCompletion":"2015-09","completion":"2015-09","firstPosted":"2010-05-04","resultsPosted":"2016-10-27","lastUpdate":"2020-12-22"},"enrollment":221,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Heart Failure"],"interventions":[{"type":"DRUG","name":"Eplerenone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Eplerenone arm","type":"EXPERIMENTAL"},{"label":"Placebo arm","type":"PLACEBO_COMPARATOR"}],"summary":"A study to compare the efficacy and safety of eplerenone in Japanese chronic heart failure patients with placebo.","primaryOutcome":{"measure":"Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF)","timeFrame":"Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)","effectByArm":[{"arm":"Eplerenone","deltaMin":33,"sd":null},{"arm":"Placebo","deltaMin":36,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"55 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":54,"countries":["Japan"]},"refs":{"pmids":["28824029"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":111},"commonTop":["Nasopharyngitis","Cardiac failure","Fall","Constipation","Hyperuricaemia"]}}